Cassava's Stock Drops After It Agrees to Pay $40M to Settle SEC Alzheimer's Claims
Cassava Sciences shares dropped after the company agreed to a $40 million settlement with the Securities and Exchange Commission over charges that it manipulated clinical trial data related to its Alzheimer’s disease drug.
Bristol Myers trades higher after the FDA approves an oral medication for schizophrenia in adults, fiscal fourth-quarter ...
Cassava Sciences has agreed to pay $40 million to resolve an investigation into claims it made m | Cassava Sciences has ...
Despite the settlement, the Securities and Exchange Commission on Thursday sued Cassava Sciences in the Western District ...
Today, Benzinga 's options scanner spotted 15 uncommon options trades for Cassava Sciences. This isn't normal. The overall ...
Cassava Sciences' shares dropped 13% after the SEC announced a $40 million settlement related to misleading claims about the results of a 2020 Phase II trial for its Alzheimer's drug, simufilam. The ...
Cassava's financial challenges and data integrity concerns remain critical. Learn why SAVA stock is rated a strong sell given ...
MeridianLink announced an underwritten secondary public offering of 6 million shares by funds managed by Thoma Bravo. The selling stockholders plan to grant the underwriter an option to purchase up to ...
AUSTIN, Texas, Sept. 26, 2024 (GLOBE NEWSWIRE) -- (“Cassava” or the “Company”) (Nasdaq: SAVA), a biotechnology company ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback